EN CN

PIPELINE

ONCOLOGY

(MAH Pilot Project)

CAN008

MORE

TERRITORY

Greater China

(including HK, Macau and Taiwan)

INDICATION

Glioblastoma multiforme

DEVELOPMENT STATUS

China IND

Taiwan Phase 1

CAN017

MORE

TERRITORY

Global

(except North America)

INDICATION

Squamous cell esophageal cancer

DEVELOPMENT STATUS

China IND

CAN002

MORE

TERRITORY

China

INDICATION

Mucositis caused by radiation or high dose chemotherapy

DEVELOPMENT STATUS

China MAA

RARE DISEASE

CANbridge launched rare disease business platform to commercialize Western rare disease therapies via an innovative business approach in China.

Focused therapeutic areas

  • Chronic diseases with official rare disease designations.

  • Serious & debilitating diseases excluding cancers.

  • Genetic diseases with unique genetic profile/prevalence in China.

  • Significant unmet medical needs in China.

MORE